• Explore /
  • Poster
  • / Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).

Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).

Abstract Poster

Authors

null

Haeseong Park

Dana-Farber Cancer Institute, Boston, MA

Haeseong Park , Susan Michelle Geyer , Kelsey Klute , Jonathan Bleeker , Daniel King , Matthew Strickland , Austin Goodrich , Destin Carlisle , Ardaman Shergill , Eileen Mary O'Reilly , Jeffrey A. Meyerhardt , Manish A. Shah

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT05677490

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS4175)

DOI

10.1200/JCO.2023.41.16_suppl.TPS4175

Abstract #

TPS4175

Poster Bd #

494a

Abstract Disclosures

Similar Posters

First Author: Shintaro Nakano

First Author: Elisa Giommoni

First Author: Syvart Dennen

First Author: Philip Agop Philip